1. Home
  2. RPGL vs LEXX Comparison

RPGL vs LEXX Comparison

Compare RPGL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RPGL

Republic Power Group Limited Class A Ordinary Shares

N/A

Current Price

$1.16

Market Cap

14.7M

Sector

Technology

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

N/A

Current Price

$0.72

Market Cap

16.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RPGL
LEXX
Founded
2015
2004
Country
Singapore
Canada
Employees
N/A
7
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7M
16.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RPGL
LEXX
Price
$1.16
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
850.7K
135.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
$21.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.46
52 Week High
$8.44
$1.90

Technical Indicators

Market Signals
Indicator
RPGL
LEXX
Relative Strength Index (RSI) 47.48 49.49
Support Level $0.30 $0.58
Resistance Level $2.69 $0.83
Average True Range (ATR) 0.82 0.07
MACD -0.15 0.01
Stochastic Oscillator 10.61 42.83

Price Performance

Historical Comparison
RPGL
LEXX

About RPGL Republic Power Group Limited Class A Ordinary Shares

Republic Power Group Ltd is a Singapore-based provider of customized software development, technology solutions, consulting, and technical support services. The company specializes in real-time monitoring, resource allocation, surveillance, and threat detection software, with capabilities in AI and IoT integration to provide services to corporate clients and government agencies.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: